Chronic Lymphocytic Leukemia Articles | Page 2

Acalabrutinib Among Exciting Options Emerging in CLL
Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.
Profiling CLL Patients Likely to Progress on Available Agents
The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.
Recognizing Secondary Malignancies in CLL
Alessandra Ferrajoli, MD, discusses the risks of developing secondary malignancies in patients with chronic lymphocytic leukemia.
Expert Discusses Ongoing Advances in CLL
Farrukh Awan, MD, discusses novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.
Wierda Discusses Novel Combinations, Sequencing in CLL
William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.
High Response Rate, MRD Negativity Confirmed for Venetoclax in CLL
Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.
CAR T-Cell Therapy Active in High-Risk, Refractory CLL
Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014. 
Venetoclax Combination Improves PFS in Phase III CLL Trial
The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),
FDA Accepts Application for Rituximab Biosimilar
The FDA has accepted a biologics license application for the rituximab biosimilar Rixathon, according to Sandoz, the company developing the treatment.
FDA Places Holds on Several Durvalumab Combination Trials
The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies.
Publication Bottom Border
Border Publication
x